US EditionPublished • loading... • Updated
GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients
Psoriasis patients using GLP-1 receptor agonists had 78% lower mortality and 44% fewer major cardiovascular events; risks of alcohol and substance abuse also decreased, study finds.
- Researchers revealed in Paris on September 17, 2025, that GLP-1 receptor agonists are associated with reduced mortality and lower cardiovascular risk among psoriasis patients in the United States.
- The study examined data from more than 6,000 individuals with psoriasis who also had diabetes or obesity and received continuous treatment for two years with either GLP-1 receptor agonists or alternative anti-diabetic medications, with groups balanced for age, gender, and existing health conditions.
- GLP-1RA users showed a 78% lower risk of death, a 44% reduced risk of major cardiovascular events, plus a 65% drop in alcohol abuse and nearly 50% in substance abuse compared to controls.
- Lead author Professor Ralf Ludwig explained that GLP-1 receptor agonists could provide advantages that extend past their typical roles in managing weight and blood sugar, including potential improvements in cardiovascular health and mental well-being among individuals with psoriasis.
- These findings emphasize that psoriasis management should address wider health risks, as GLP-1RAs offer a safe, dual benefit potentially making them preferred therapy for psoriasis patients with metabolic needs.
Insights by Ground AI
21 Articles
21 Articles
Watauga Democrat+18 Reposted by 18 other sources
Ozempic, Zepbound Offer Unexpected Benefits For Psoriasis Patients
Key Takeaways
·Calhoun, United States
Read Full Article
GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients
Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.
·United States
Read Full Article
Research shows GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients
Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.
Coverage Details
Total News Sources21
Leaning Left1Leaning Right6Center5Last UpdatedBias Distribution50% Right
Bias Distribution
- 50% of the sources lean Right
50% Right
C 42%
R 50%
Factuality
To view factuality data please Upgrade to Premium
